1407-47-2

• 常用中文名：血管紧张素
• 常用英文名：Angiotensin
• CAS号：1407-47-2
• 分子式：C₆₂H₈₉N₁₇O₁₄
• 分子量：1296.48000
• 相关类别： 原料药 循环系统用药 抗休克血管活性药
• 发布时间：2018-05-09 08:00:00
• 更新时间：2024-01-02 15:33:59

• 升血压药。主要用于外伤性或手术后休克和全身或腰椎麻醉所致的低血压。
  

名称

• 中文名: 血管紧张素
• 英文名: Angiotensin
• 中文别名: 增血压素
• 英文别名: ANGIOTENSINII,HYPERTENSIN; angiotensin I; Hypertensin

物化性质

• 密度: 1.48g/cm3
• 分子式: C₆₂H₈₉N₁₇O₁₄
• 分子量: 1296.48000
• 精确质量: 1295.68000
• PSA: 493.22000
• LogP: 3.83280
• 折射率: 1.679
• 储存条件: 库房通风低温干燥,与食品原料分开存放
• 稳定性:

  本品为合成的八肽增血压素，是天然血管紧张肽Ⅱ的化学合成类似物，两者的差异在5位上，本品为缬氨酸，而天然的为异亮氨酸。为白色或类白色粉末，易溶于水，溶于甲醇、乙醇、丙二醇，不溶于乙醚、氯仿等。在干燥空气中稳定，在水溶液中逐渐分解为氨和α-L-血管紧张肽。; 天然血管紧张肽Ⅱ在体内由人体血浆α2-球蛋白的血管紧张肽原酶经酶裂解后转化而成，具有强烈的血管收缩作用，能特异地引起血压上升。较去甲肾上腺素强40倍。本品活性是血管紧张肽Ⅱ的两倍。

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : BW2275000 CHEMICAL NAME : Angiotonin CAS REGISTRY NUMBER : 1407-47-2 LAST UPDATED : 199012 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 8 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : 27ZIAQ "Drug Dosages in Laboratory Animals - A Handbook," Rev. ed., Barnes, C.D., and L.G. Eltherington, Berkeley, Univ. of California Press, 1973 Volume(issue)/page/year: -,43,1973 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 10 mg/kg SEX/DURATION : female 7-12 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : JPMSAE Journal of Pharmaceutical Sciences. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.50- 1961- Volume(issue)/page/year: 58,406,1969 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 20 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - body wall REFERENCE : LIFSAK Life Sciences. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1-8, 1962-69; V.14- 1974- Volume(issue)/page/year: 8,525,1969 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 20 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - homeostasis Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) REFERENCE : LIFSAK Life Sciences. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1-8, 1962-69; V.14- 1974- Volume(issue)/page/year: 8,525,1969 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 200 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death REFERENCE : LIFSAK Life Sciences. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1-8, 1962-69; V.14- 1974- Volume(issue)/page/year: 8,525,1969